Skip to content
drillr.ai
Sign up

PEPG

PepGen Inc.

NASDAQ · Healthcare · Biotechnology · US

$3.11
−2.20%
Ask drillr

  • Aug 6, 2026, 11:32 UTC

    PepGen reported its financial results for the second quarter of 2026.

    Source:

  • Aug 6, 2026, 11:30 UTC

    PepGen announced it will advance its drug candidate PGN-EDODM1 into the highest dose cohort in the Phase 2 FREEDOM2-DM1 study following a Data Safety Monitoring Board review.

    Source: